Interim analysis of an open-label extension in Crohn's disease: of 430 patients on mirikizumab for 2 years, 60.5% had endoscopic response, 37.9% endoscopic remission and 73.4% CDAI remission at week 104; 7.7% had serious adverse events in year 2.
RCTn = 465
Sands et al. Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial